نتایج جستجو برای: میلوم متعدد multiple myeloma

تعداد نتایج: 775499  

Journal: :Molecular cancer therapeutics 2016
Shirong Li Jing Fu Caisheng Lu Markus Y Mapara Shahzad Raza Ulrich Hengst Suzanne Lentzsch

eIF4E is the key regulator of protein translation and critical for translation. The oncogenic potential of tumorigenesis, which is highly contingent on cap-dependent eIF4E, also arises from the critical role in the nuclear export and cytosolic translation of oncogenic transcripts. Inhibition of Exportin1 (XPO1), which is the major nuclear export protein for eIF4E-bound oncoprotein mRNAs, result...

2011
Mala Mahto Priya Balakrishnan Bidhan Chandra Koner Pramod Lali Tarun Kumar Mishra Alpana Saxena

Introduction: Multiple myeloma is characterized by plasma cell infiltration of the bone marrow and presence of a monoclonal protein in plasma and/or the urine. Multiple myeloma with biclonal gammopathy is rare (1%). Case Report: In this report, we describe a case of biclonal multiple myeloma having two M bands on serum protein electrophoresis. He had elevated serum IgG and IgA levels. Ig G and ...

Journal: :Journal of clinical pathology 2007
Chor-Sang Chim Raymond Liang Man-Hin Leung Yok-Lam Kwong

Malignant transformation is a multistep process that may involve dysregulation of oncogenes and tumour suppressor genes, and monoclonal gammopathy of undetermined significance (MGUS) is believed to be a precursor of multiple myeloma. To investigate whether aberrant promoter methylation might be involved in the evolution of MGUS to multiple myeloma, we examined the p16, protein tyrosine phosphat...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2017
Xiaoyan Feng Li Zhang Chirag Acharya Gang An Kenneth Wen Lugui Qiu Nikhil C Munshi Yu-Tzu Tai Kenneth C Anderson

Purpose: We study CD38 levels in immunosuppressive CD4+CD25highFoxp3+ regulatory T cells (Treg) and further define immunomodulating effects of a therapeutic CD38 mAb isatuximab/SAR650984 in multiple myeloma.Experimental Design: We evaluated percentages of CD38-expressing subsets in Tregs from normal donors and multiple myeloma patients. Peripheral blood mononuclear cells (PBMC) were then treate...

Journal: :Molecular cancer therapeutics 2014
Diana Cirstea Loredana Santo Teru Hideshima Homare Eda Yuko Mishima Neeharika Nemani Anuj Mahindra Andrew Yee Gullu Gorgun Yiguo Hu Hiroto Ohguchi Rikio Suzuki Francesca Cottini Sylvie M Guichard Kenneth C Anderson Noopur Raje

Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma, resistance to these drugs may arise via feedback activation loops. This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), because IGF1R signaling is downregulated by multiple AKT and mTOR feedback mechanisms. We have tested this hypothesis in multiple myeloma using the novel select...

Journal: :Thorax 2006
D B Marmor J L Farber J E Gottlieb

Pulmonary involvement with multiple myeloma occurs infrequently and may be difficult to distinguish from more common primary lung tumours, metastatic disease, or other pleural and parenchymal abnormalities. A patient who developed acute respiratory distress syndrome (ARDS) was subsequently found to have multiple myeloma with involvement of lung parenchyma by neoplastic plasma cells. Only one ot...

2013
Dharminder Chauhan Arghya Ray Kristina Viktorsson Jack Spira Claudia Paba-Prada Nikhil Munshi Paul Richardson Rolf Lewensohn Kenneth C. Anderson

Purpose: The alkylating agentmelphalan prolongs survival in patients withmultiplemyeloma; however, it is associated with toxicities and development of drug-resistance. Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen), a novel dipeptide prodrug of melphalan in multiple myeloma. Experimental Design: Multiple myeloma cell lines, primary patient cells, and the human multiple my...

ژورنال: :annals of military and health science research 0
سامان خرمی نژاد حسن جلائی خو احمد ذاکری فر محمد علی هاشمی

سابقه و هدف: پلاسماسیتوما در گروه سنی بالاتر از 25 سال، میزان بروز 30 در هر صدهزار نفر دارد. این نوع بیماری سه نوع تظاهر بالینی دارد. 1) میلوم مولتیپل 2) پلاسماسیتومای منفرد استخوانی 3) پلاسماسیتومای اکسترامدولری. در این مقاله به معرفی یک خانم مبتلا اقدام گردیده است.   معرفی بیمار: بیمار خانم 57 ساله ای بود که یکسال قبل تشخیص میلوم مولتیپل برای ایشان داده شده بود علیرغم شیمی درمانی با دیسترس تن...

2016
Muhammad Husnain Sandra Kurtin Nikki Barkett Irbaz Bin Riaz Amit Agarwal

Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells which was studied in phase I/II tria...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Mariateresa Fulciniti Teru Hideshima Claudine Vermot-Desroches Samantha Pozzi Puru Nanjappa Zhenxin Shen Nipun Patel Ernest S Smith Wei Wang Rao Prabhala Yu-Tzu Tai Pierfrancesco Tassone Kenneth C Anderson Nikhil C Munshi

PURPOSE We investigated the in vitro and in vivo anti-multiple myeloma activity of monoclonal antibody (mAb) 1339, a high-affinity fully humanized anti-interleukin 6 mAb (immunoglobulin G1), alone and in combination with conventional and novel anti-multiple myeloma agents, as well as its effect on bone turnover. EXPERIMENTAL DESIGN We examined the growth inhibitory effect of 1339 against mult...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید